- Home
- WGS vs NVCR Comparison
WGS vs NVCR Comparison
Compare WGS & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGS
- NVCR
- Stock Information
- Founded
- WGS 2017
- NVCR 2000
- Country
- WGS United States
- NVCR Jersey
- Employees
- WGS N/A
- NVCR N/A
- Industry
- WGS Retail: Computer Software & Peripheral Equipment
- NVCR Medical/Dental Instruments
- Sector
- WGS Technology
- NVCR Health Care
- Exchange
- WGS Nasdaq
- NVCR Nasdaq
- Market Cap
- WGS 1.5B
- NVCR 1.8B
- IPO Year
- WGS N/A
- NVCR 2015
- Fundamental
- Price
- WGS $68.43
- NVCR $16.11
- Analyst Decision
- WGS Strong Buy
- NVCR Buy
- Analyst Count
- WGS 5
- NVCR 5
- Target Price
- WGS $67.00
- NVCR $26.60
- AVG Volume (30 Days)
- WGS 753.8K
- NVCR 955.2K
- Earning Date
- WGS 10-29-2024
- NVCR 10-30-2024
- Dividend Yield
- WGS N/A
- NVCR N/A
- EPS Growth
- WGS N/A
- NVCR N/A
- EPS
- WGS N/A
- NVCR N/A
- Revenue
- WGS $267,228,000.00
- NVCR $577,738,000.00
- Revenue This Year
- WGS $43.70
- NVCR $19.13
- Revenue Next Year
- WGS $16.78
- NVCR $5.33
- P/E Ratio
- WGS N/A
- NVCR N/A
- Revenue Growth
- WGS 29.41
- NVCR 14.63
- 52 Week Low
- WGS $1.29
- NVCR $11.29
- 52 Week High
- WGS $89.11
- NVCR $24.74
- Technical
- Relative Strength Index (RSI)
- WGS 51.05
- NVCR 44.79
- Support Level
- WGS $71.45
- NVCR $17.28
- Resistance Level
- WGS $82.18
- NVCR $18.38
- Average True Range (ATR)
- WGS 7.58
- NVCR 1.12
- MACD
- WGS -1.36
- NVCR -0.04
- Stochastic Oscillator
- WGS 17.21
- NVCR 28.29
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx, which derives maximum revenue and Legacy Sema4 diagnostics.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.